Activated F IX concentrate (FEIBA) used in the treatment of haemophilic patients with antibody to F VIII.
Bleeding episodes in five haemophiliacs with antibody to F VIII were treated by activated F IX concentrate (FEIBA). Relief of pain and haemostasis in affected muscles and joints were recorded in each case. One patient developed a mild attack of disseminated intravascular coagulation with an uneventful recovery. A substantial rise in natural inhibitors of coagulation was seen in two patients, and all but one experienced a rise in F VIII antibody titer.
D000328:Adult; D000991:Antithrombins / Q000032:analysis; D001777:Blood Coagulation / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D003450:Cryoglobulins / Q000627:therapeutic use; D004341:Drug Evaluation; D005164:Factor IX / Q000008:administration & dosage / Q000627:therapeutic use*; D005169:Factor VIII / Q000276:immunology*; D006467:Hemophilia A / Q000188:drug therapy*; D006801:Humans; D007518:Isoantibodies / Q000032:analysis; D008297:Male
D000991:Antithrombins; D003450:Cryoglobulins; D007518:Isoantibodies; D005169:Factor VIII; D005164:Factor IX